Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhibitor that may be better tolerated by patients who...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Ferrata Storti Foundation 2021-03-01
Schriftenreihe:	Haematologica
Online-Zugang:	https://haematologica.org/article/view/10212
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!